← Back to Search

Vitamin

Nicotinamide Riboside for Gulf War Syndrome

N/A

Recruiting

Led By Amanpreet Cheema, PhD

Research Sponsored by Roskamp Institute Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition

Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 weeks

Awards & highlights

Study Summary

This trial will test whether a 300 mg dose of Nicotinamide Riboside can increase plasma NAD+ levels in participants with Gulf War Illness.

Who is the study for?

This trial is for Gulf War veterans aged 47-70 with Gulf War Illness, who are medically stable and not on certain supplements. Women must use birth control if of childbearing potential. Those with allergies to the study drug or significant health issues can't participate.Check my eligibility

What is being tested?

The trial tests if Nicotinamide Riboside (NR) increases plasma NAD+ levels in GWI patients using a double-blind method where neither participants nor researchers know who gets NR or placebo until after results are collected.See study design

What are the potential side effects?

While specific side effects aren't listed here, NR is generally considered safe but could potentially cause mild upset stomach, fatigue, headaches, diarrhea, or indigestion.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a veteran diagnosed with Gulf War Illness according to CDC or Kansas criteria.

Select...

My weight is between 110 lbs and 440 lbs.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in plasma NAD+ levels

Secondary outcome measures

Changes in immune biomarker profiles

Changes in lipid profiles

Other outcome measures

Fatigue

Changes in general well-being

Memory

+3 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Study Supplement: NRActive Control1 Intervention

26 subjects will take the supplement (nicotinamide riboside) during the first phase of the study. 300mg will be taken once a day for the 10-week period in phase one.

Group II: ControlPlacebo Group1 Intervention

26 subjects will take the placebo during the first phase of the study (10 weeks).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Roskamp Institute Inc.Lead Sponsor

6 Previous Clinical Trials

474 Total Patients Enrolled

1 Trials studying Gulf War Syndrome

100 Patients Enrolled for Gulf War Syndrome

United States Department of DefenseFED

865 Previous Clinical Trials

327,647 Total Patients Enrolled

7 Trials studying Gulf War Syndrome

435 Patients Enrolled for Gulf War Syndrome

Nova Southeastern UniversityOTHER

89 Previous Clinical Trials

11,589 Total Patients Enrolled

2 Trials studying Gulf War Syndrome

330 Patients Enrolled for Gulf War Syndrome

Media Library

Nicotinamide Riboside (Vitamin) Clinical Trial Eligibility Overview. Trial Name: NCT05243290 — N/A

Gulf War Syndrome Research Study Groups: Study Supplement: NR, Control

Gulf War Syndrome Clinical Trial 2023: Nicotinamide Riboside Highlights & Side Effects. Trial Name: NCT05243290 — N/A

Nicotinamide Riboside (Vitamin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05243290 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the population size of the current clinical trial?

"That is correct. The online database hosted on clinicaltrials.gov reveals that this medical investigation initiated recruitment in mid-April and requires the inclusion of 52 people from two different study locations."

Answered by AI

Is the research team actively seeking participants for this trial?

"A review of clinicaltrials.gov's database indicates that this research study is presently inviting participants to join. Initially posted on April 13th 2022, the trial was recently updated on April 25th 2022."

Answered by AI

Does the eligibility for this experimental study encompass individuals under 25 years of age?

"Patients aged 47 and older, but still under 65 years of age are eligible to participate in this research."

Answered by AI

What criteria must be met to participate in this medical experiment?

"This trial seeks 52 people between the ages of 47 and 65 living with Gulf War Illness. In order to be eligible, candidates must: possess both genders, originate from diverse backgrounds, voluntarily provide informed consent, demonstrate stable medical health through a physician's evaluation; if female of childbearing age they must use birth control throughout the study and 30 days after its completion; have body weight ranging from 50-200 kg (110 - 440 lbs); have been deployed during the time period August 1990 -August 1991) as well as meet criteria for CMI or Kansas GWI definition established by Centers for Disease Control & Prevention."

Answered by AI

Recent research and studies

Journal of NeurochemistryJournal

REVIEW: Vitamin Transport and Homeostasis in Mammalian Brain: Focus on Vitamins B and E

Spector, Reynold, and Conrad E. Johanson. 2007. “REVIEW: Vitamin Transport and Homeostasis in Mammalian Brain: Focus on Vitamins B and E”. Journal of Neurochemistry. Wiley. doi:10.1111/j.1471-4159.2007.04773.x.

NeuroToxicologyJournal

Targeting Sirtuin Activity with Nicotinamide Riboside Reduces Neuroinflammation in a GWI Mouse Model

Joshi, Utsav, James E. Evans, Andrew Pearson, Nicole Saltiel, Adam Cseresznye, Teresa Darcey, Joseph Ojo, et al.. 2020. “Targeting Sirtuin Activity with Nicotinamide Riboside Reduces Neuroinflammation in a GWI Mouse Model”. Neurotoxicology. Elsevier BV. doi:10.1016/j.neuro.2020.04.006.

CortexJournal

Recent Research on Gulf War Illness and Other Health Problems in Veterans of the 1991 Gulf War: Effects of Toxicant Exposures During Deployment

White, Roberta F., Lea Steele, James P. O'Callaghan, Kimberly Sullivan, James H. Binns, Beatrice A. Golomb, Floyd E. Bloom, et al.. 2016. “Recent Research on Gulf War Illness and Other Health Problems in Veterans of the 1991 Gulf War: Effects of Toxicant Exposures During Deployment”. Cortex. Elsevier BV. doi:10.1016/j.cortex.2015.08.022.

clinicaltrials.govStudy